Skip to main content

Table 3 Patient, cancer, and chemotherapy characteristics

From: Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases

 

All patients (n=357)

Gold standard (n=82)

FN Patients: neutropenia, primary position (n=54)

FN Patients: neutropenia, any position (n=71)

FN Patients: Neutropenia + Fever,Any Position (n=28)

FN Patients: neutropenia or fever, any position (n=78)

FN Patients: neutropenia, fever, or infection, any position (n=201)

Patient

  

 Age (years), mean±SD

64.2±13.0

62.1±13.8

63.3±15.1

62.6±14.8

61.3±16.3

63.0±14.5

65.5±12.3

 Male, %

56.0

51.2

42.6

40.9

39.3

44.9

56.2

 Body Mass Index (kg/m2), mean±SD

27.3±5.9

27.8±4.5

27.8±4.7

28.1±4.7

28.1±5.7

28.2±5.1

27.3±5.2

 N

332

77

51

67

28

74

192

 Absolute Neutrophil Count  (cells/L), mean±SD

4.4±5.6

0.2±0.3

0.3±0.9

0.9±3.3

0.2±0.2

1.1±3.5

4.4±6.3

 N

357

82

54

71

28

78

201

Cancer

       

 Type %

       

  Bone, Connective Tissue, Skin, Breast

   Female Breast

9.8

19.5

18.5

18.3

28.6

17.9

11.9

   Other

2.8

1.2

1.9

2.8

3.6

2.6

2.5

  Respiratory and Intrathoracic Organs

   Trachea, Bronchus, Lung

19.3

17.1

9.3

9.9

14.3

10.3

20.9

   Other

1.4

2.4

5.6

4.2

3.6

3.8

2.0

  Digestive Organs and Peritoneum

   Colon/Rectum

10.9

9.8

5.6

5.6

7.1

5.1

9.5

   Pancreas

7.8

1.2

1.9

2.8

0.0

5.1

7.0

   Esophagus

2.5

2.4

0.0

0.0

0.0

0.0

1.0

   Other

3.1

0.0

0.0

0.0

0.0

0.0

2.0

  Non-Hodgkin's Lymphoma

11.2

20.7

25.9

23.9

28.6

24.4

14.9

  Genitourinary Organs

   Bladder

4.2

3.7

3.7

4.2

0.0

3.8

5.0

   Ovarian

3.6

1.2

5.6

4.2

0.0

3.8

3.0

   Prostate

2.8

0.0

0.0

0.0

0.0

0.0

3.0

   Uterus

1.7

0.0

0.0

1.4

0.0

1.3

0.5

   Other

2.8

1.2

1.9

1.4

0.0

1.3

2.0

  Lip, Oral Cavity, and Pharnyx

2.0

1.2

0.0

0.0

0.0

0.0

1.5

  Blood Cancers

6.7

13.4

13.0

14.1

14.3

14.1

8.0

  Hodgkin’s Lymphoma

1.7

1.2

1.9

1.4

0.0

1.3

0.5

  Other

5.6

3.7

5.6

5.6

0.0

5.1

5.0

 Presence of Metastases, %

35.0

24.4

22.2

21.1

17.9

20.5

26.4

Chemotherapy

 No. of Myelosuppressive Drugs in Cycle 1, %

  1

32.2

20.6

26.1

27.4

38.1

29.4

29.2

  2

47.2

50.7

45.7

46.8

38.1

44.1

49.7

  ≥3

20.6

28.8

28.3

25.8

23.8

26.5

21.1

 Year of Initiation, %

       

  2004-2005

41.7

37.8

42.6

42.3

14.3

39.7

37.3

  2006-2007

28.3

28.1

22.2

23.9

32.1

23.1

31.4

  2008-2010

30.0

34.2

35.2

33.8

53.6

37.2

31.3